Oxurion Nv

Oxurion Nv company information, Employees & Contact Information

Explore related pages

Related company profiles:

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Company Details

Employees
35
Address
Gaston Geenslaan 1, Leuven,3001,belgium
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Leuven
Looking for a particular Oxurion Nv employee's phone or email?

Oxurion Nv Questions

News

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC - Actusnews

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actusnews

Oxurion provides an update related to its investment strategy in digital assets - Actusnews

Oxurion provides an update related to its investment strategy in digital assets Actusnews

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas - Actusnews

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Actusnews

Oxurion : Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC - MarketScreener

Oxurion : Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC MarketScreener

Oxurion to file for bankruptcy following trial failure - Clinical Trials Arena

Oxurion to file for bankruptcy following trial failure Clinical Trials Arena

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas - Yahoo Finance

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas Yahoo Finance

Oxurion Nv : Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis - MarketScreener

Oxurion Nv : Oxurion signs letter of intent for the contemplated acquisition of a CRO with strong complementarity to Axiodis MarketScreener

Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to… - Actusnews

Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to… Actusnews

Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO - Actusnews

Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO Actusnews

Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify… - Actusnews

Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify… Actusnews

Oxurion plans to launch a treasury diversification strategy into digital assets under a EUR 10M indicative… - Actusnews

Oxurion plans to launch a treasury diversification strategy into digital assets under a EUR 10M indicative… Actusnews

Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO - Actusnews

Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO Actusnews

Oxurion plans bankruptcy filing as phase 2 eye disease failure evaporates remaining optimism - Fierce Biotech

Oxurion plans bankruptcy filing as phase 2 eye disease failure evaporates remaining optimism Fierce Biotech

Will Oxurion NV (TG40) stock benefit from mergers - July 2025 Rallies & Weekly Market Pulse Alerts - Trung tâm Dự báo KTTV quốc gia

Will Oxurion NV (TG40) stock benefit from mergers - July 2025 Rallies & Weekly Market Pulse Alerts Trung tâm Dự báo KTTV quốc gia

Oxurion discontinues the development of THR-687 despite promising preclinical data - Pharmaceutical Technology

Oxurion discontinues the development of THR-687 despite promising preclinical data Pharmaceutical Technology

Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect - Fierce Biotech

Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect Fierce Biotech

Oxurion stops investing in cancer spinout, reduces head count - Fierce Biotech

Oxurion stops investing in cancer spinout, reduces head count Fierce Biotech

Oxurion reports mixed results from Phase IIa DME study - Clinical Trials Arena

Oxurion reports mixed results from Phase IIa DME study Clinical Trials Arena

Top Oxurion Nv Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant